Ahmet Emre Eskazan,Deniz Ozmen.Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?[J].2017,10(7).Eskazan AE, Ozmen D. Tyrosine kinase inhibitor (TKI) therapy for ...
Papoian, "Tyrosine kinase inhibitor (TKI)- induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome," Journal of Applied Toxicology, vol. 32, no. 12, pp. 945-951, 2012.Yang B, Papoian T. Tyrosine kinase inhibitor (TKI)-induced ...
discontinuation of multi-kinase inhibitor (MKIs), imatinib therapy due to TKI-associated adverse effects.10Toxicity can be attributed to bothon-targeteffects through excessive inhibition of the intended TK function; and/oroff-targeteffects resulting from the simultaneous inhibition of multiple other kinas...
The clinical benefit of tyrosine kinase inhibitors (TKIs)-based systemic therapy for advanced hepatocellular carcinoma (HCC) is limited due to drug resistance. Here, we uncover that lipid metabolism reprogramming mediated by unconventional prefoldin RPB5 interactor (URI) endows HCC with resistance to TK...
In general, resistance mutations may overlap and vary between TKIs, which may be related to the types of the kinase. Therefore, if a resistance mutation occurs during TKI therapy, changing the TKI may be helpful. However, it is not a long-term solution. Cancer cells gradually develop resistan...
TKI(s): tyrosine kinase inhibitor(s).References Sawyers C: Targeted cancer therapy. Nature. 2004, 432: 294-297. 10.1038/nature03095 CAS PubMed Google Scholar Shawver LK, Slamon D, Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002, 1: 117-123. 10.101...
The second promising tyrosine kinase inhibitor against MTC,motesanib diphosphate(AMG-706), is a multikinase inhibitor targeting VEGF, platelet-derived growth factor, and Kit receptors, which lead toantiangiogenicand directantitumor activity. In a phase I trial with AMG-706, one patient with MTC exhi...
tyrosine kinases have emerged as major targets for drug discovery [4,5]. A tyrosine kinase inhibitor (TKI) is designed to inhibit the corresponding kinase from playing its role of catalyzing phosphorylation [6]. Since US Food and Drug Administration (FDA) approved imatinib for the treatment of ...
In line with this finding, we found a cooperative effect when the tyrosine kinase inhibitor (TKI) dasatinib11 was combined with CHOEP in vitro and in vivo. Given dasatinib efficacy and tolerability when administered for the treatment of chronic myeloid leukaemia (CML) and acute lymphoblastic ...
Controversies in renal cell carcinoma: Treatment choice after progression on vascular endothelial growth factor-targeted therapy The mammalian target of rapamycin inhibitor (mTORI) everolimus and the tyrosine kinase inhibitor (TKI) axitinib are the only two post-first-line treatment ... E Calvo,V Gr...